Cover Image
市場調查報告書

過敏性鼻炎:現在·未來市場參與企業

Allergic Rhinitis - Current and Future Players

出版商 GlobalData 商品編碼 371770
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎:現在·未來市場參與企業 Allergic Rhinitis - Current and Future Players
出版日期: 2015年09月01日 內容資訊: 英文 82 Pages
簡介

本報告提供全球過敏性鼻炎 (AR) 治療藥市場上現有/新加入企業相關分析,提供您整體市場的未來展望和促進·阻礙因素,現在·未來的競爭趨勢,主要企業簡介(企業概要,企業發展,財務狀況,SWOT分析)等調查。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進·阻礙因素:全球市場課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Merck & Co.
    • GlaxoSmithKline
    • 大日本住友製藥
    • Sanofi
    • Teva
    • Meda AB

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1054FPR

GlobalData has released its pharma report, "Allergic Rhinitis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Allergic Rhinitis Market. The report identifies and analyses the key companies shaping and driving the global Allergic Rhinitis market. The report provides insight into the competitive Allergic Rhinitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Allergic Rhinitis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Allergic Rhinitis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Allergic Rhinitis market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Allergic Rhinitis market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Major Companies
    • 4.3.1. Merck & Co.
    • 4.3.2. GlaxoSmithKline
    • 4.3.3. Sumitomo Dainippon Pharma
    • 4.3.4. Sanofi
    • 4.3.5. Teva
    • 4.3.6. Meda AB

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Pediatric Allergic Rhinitis Population
    • 5.4.2. Diagnosed AR Patients
    • 5.4.3. Percentage of Drug-Treated Patients
    • 5.4.4. Drugs Included in Each Therapeutic Class
    • 5.4.5. Launch and Patent Expiry Dates
    • 5.4.6. 1General Pricing Assumptions
    • 5.4.7. Individual Drug Assumptions
    • 5.4.8. Generic Erosion
    • 5.4.9. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in This Study
  • 5.6. About the Authors
    • 5.6.1. Analyst
    • 5.6.2. Therapy Area Director
    • 5.6.3. Epidemiologist
    • 5.6.4. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for AR, 2014-2024
  • Table 2: Global AR Market - Drivers and Barriers, 2014-2024
  • Table 3: Major Companies in the AR Market and Their Portfolios, 2014
  • Table 4: Merck's AR Portfolio Assessment, 2014
  • Table 5: GSK's AR Portfolio Assessment, 2014
  • Table 6: Sumitomo Dainippon Pharma's AR Portfolio Assessment, 2014
  • Table 7: Sanofi's AR Portfolio Assessment, 2014
  • Table 8: Teva's AR Portfolio Assessment, 2014
  • Table 9: Meda's AR Portfolio Assessment, 2014
  • Table 10: Abbreviations
  • Table 11: Key Launch Dates of the Currently Available AR Therapies
  • Table 12: Key Loss of Exclusivity Dates of the Currently Available AR Therapies
  • Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for AR by Region, 2014-2024
  • Figure 2: Company Portfolio Gap Analysis in AR, 2014-2024
Back to Top